Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP496336.RATbVVzMWWY1gKEfRoAa2uIdB7rG-mxmzr0p8H3s03qYg130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP496336.RATbVVzMWWY1gKEfRoAa2uIdB7rG-mxmzr0p8H3s03qYg130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP496336.RATbVVzMWWY1gKEfRoAa2uIdB7rG-mxmzr0p8H3s03qYg130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP496336.RATbVVzMWWY1gKEfRoAa2uIdB7rG-mxmzr0p8H3s03qYg130_provenance.
- befree-20150227 importedOn "2015-02-27" NP496336.RATbVVzMWWY1gKEfRoAa2uIdB7rG-mxmzr0p8H3s03qYg130_provenance.
- NP496336.RATbVVzMWWY1gKEfRoAa2uIdB7rG-mxmzr0p8H3s03qYg130_assertion wasGeneratedBy ECO_0000203 NP496336.RATbVVzMWWY1gKEfRoAa2uIdB7rG-mxmzr0p8H3s03qYg130_provenance.
- NP496336.RATbVVzMWWY1gKEfRoAa2uIdB7rG-mxmzr0p8H3s03qYg130_assertion wasDerivedFrom befree-20150227 NP496336.RATbVVzMWWY1gKEfRoAa2uIdB7rG-mxmzr0p8H3s03qYg130_provenance.
- NP496336.RATbVVzMWWY1gKEfRoAa2uIdB7rG-mxmzr0p8H3s03qYg130_assertion SIO_000772 24577808 NP496336.RATbVVzMWWY1gKEfRoAa2uIdB7rG-mxmzr0p8H3s03qYg130_provenance.
- NP496336.RATbVVzMWWY1gKEfRoAa2uIdB7rG-mxmzr0p8H3s03qYg130_assertion evidence source_evidence_literature NP496336.RATbVVzMWWY1gKEfRoAa2uIdB7rG-mxmzr0p8H3s03qYg130_provenance.
- NP496336.RATbVVzMWWY1gKEfRoAa2uIdB7rG-mxmzr0p8H3s03qYg130_assertion description "[Although clinical trials have been performed with anti-IL-5 (mepolizumab) and anti-CD52 (alemtuzumab) antibodies, their therapeutic role in primary eosinophilic diseases and HES has yet to be established.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP496336.RATbVVzMWWY1gKEfRoAa2uIdB7rG-mxmzr0p8H3s03qYg130_provenance.